The Recall Desk

Manufacturer

Attix Pharmaceuticals

470 recalls in our database name Attix Pharmaceuticals as the manufacturing or recalling firm.

What the numbers show

Total
470
Critical
0
Severe
378
Most recent
2015-04-29

Of the 470 recalls from Attix Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 378 (80%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

401–425 of 470

  • HighFDA (Drugs)·D-561-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carbimazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carbimazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Carbimazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-909-2015·2015-04-29

    Sumatriptan Succinate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Sumatriptan Succinate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Sumatriptan Succinate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-670-2015·2015-04-29

    Ezetimibe API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Ezetimibe active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ezetimibe active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-519-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ammonium Tetrathiomolybdate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ammonium Tetrathiomolybdate active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Ammonium Tetrathiomolybdate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-881-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ritonavir API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ritonavir active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ritonavir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-615-2015·2015-04-29

    Attix Pharmaceuticals Recalls Daptomycin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Daptomycin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Daptomycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-570-2015·2015-04-29

    Attix Pharmaceuticals Recalls Celecoxib API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Celecoxib active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Celecoxib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-852-2015·2015-04-29

    Attix Pharmaceuticals Recalls Povidone K-30 Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Povidone K-30 pharmaceutical ingredient lots distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Povidone K-30 pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-905-2015·2015-04-29

    Sucralfate API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling sucralfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Sucralfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-502-2015·2015-04-29

    Adapalene API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling all lots of Adapalene active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Adapalene active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-644-2015·2015-04-29

    Attix Pharmaceuticals Recalls D-Penicillamine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling D-Penicillamine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    D-Penicillamine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-631-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dimethyl Fumarate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dimethyl Fumarate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Dimethyl Fumarate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-503-2015·2015-04-29

    Adenosine API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Adenosine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Adenosine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-598-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clozapine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Clozapine active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Clozapine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-650-2015·2015-04-29

    Attix Pharmaceuticals Recalls Epinephrine Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling epinephrine active pharmaceutical ingredient distributed to compounding pharmacies and research organizations due to potential penicillin cross-contamination.

    Product
    Epinephrine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-673-2015·2015-04-29

    Attix Pharmaceuticals Recalls Felbamate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Felbamate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Felbamate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-816-2015·2015-04-29

    Attix Pharmaceuticals Recalls Nevirapine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Nevirapine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Nevirapine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-808-2015·2015-04-29

    Attix Pharmaceuticals Recalls Moxifloxacin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Moxifloxacin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Moxifloxacin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-506-2015·2015-04-29

    Attix Pharmaceuticals Recalls Albuterol Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Albuterol Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Albuterol Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-936-2015·2015-04-29

    Attix Pharmaceuticals Recalls Topiramate API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Topiramate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Topiramate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-782-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methimazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling methimazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed nationwide to compounding pharmacies and research organizations.

    Product
    Methimazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-894-2015·2015-04-29

    Silver Sulfadiazine Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Silver Sulfadiazine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Silver Sulfadiazine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-871-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pyrazinamide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pyrazinamide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pyrazinamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-558-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cantharidin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of cantharidin active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Cantharidin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-581-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chlorpromazine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chlorpromazine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chlorpromazine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide